Halothane modulates the type I interferon response to influenza and minimizes the risk of secondary bacterial pneumonia through maintenance of neutrophil recruitment in an animal model

Anesthesiology

Volumn 123, Issue 3, 2015, Pages 590-602

  MacDonald, Brian A ^a,b   Chakravarthy, Krishnan V ^a,c   Davidson, Bruce A ^a,b   Mullan, Barbara A ^a,b   Alluri, Ravi ^a,b   Hakansson, Anders P ^a   Knight, Paul R ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOTHANE; INHALATION ANESTHETIC AGENT; INTERFERON;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DOG; DRUG EFFECTS; INFLUENZA A VIRUS (H1N1); KNOCKOUT MOUSE; MALE; MDCK CELL LINE; METABOLISM; MOUSE; NEUTROPHIL CHEMOTAXIS; ORTHOMYXOVIRIDAE INFECTIONS; PHYSIOLOGY; PNEUMONIA, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

ANESTHETICS, INHALATION; ANIMALS; DISEASE MODELS, ANIMAL; DOGS; HALOTHANE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INTERFERON TYPE I; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 84946919500     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000766     Document Type: Article

References (31)

1. McCullers JA: Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571-82
2. Tait AR, Knight PR: The effects of general anesthesia on upper respiratory tract infections in children. ANESTHESIoLogy 1987; 67:930-5
3. Shahangian A, Chow EK, Tian X, Kang JR, ghaffari A, Liu Sy, Belperio JA, Cheng g, Deng JC: Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009; 119:1910-20
4. Sun K, Metzger DW: Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14:558-64
5. Seo SU, Kwon HJ, Ko HJ, Byun yH, Seong BL, Uematsu S, Akira S, Kweon MN: Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog 2011; 7:e1001304
6. Davidson S, Crotta S, McCabe TM, Wack A: Pathogenic potential of interferon αβ in acute influenza infection. Nat Commun 2014; 5:3864
7. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86
8. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K: Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40
9. Brundage JF, Shanks gD: Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis 2008; 14:1193-9
10. Salo M: Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 1992; 36:201-20
11. Thomson DA: Anesthesia and the immune system. J Burn Care Rehabil 1987; 8:483-7
12. Tait AR, Davidson BA, Johnson KJ, Remick Dg, Knight PR: Halothane inhibits the intraalveolar recruitment of neutro-phils, lymphocytes, and macrophages in response to influ-enza virus infection in mice. Anesth Analg 1993; 76:1106-13
13. Tait AR, Du Boulay PM, Knight PR: Alterations in the course of and histopathologic response to influenza virus infections produced by enflurane, halothane, and diethyl ether anesthesia in ferrets. Anesth Analg 1988; 67:671-6
14. Penna AM, Johnson KJ, Camilleri J, Knight PR: Alterations in influenza A virus specific immune injury in mice anesthetized with halothane or ketamine. Intervirology 1990; 31:188-96
15. Markovic SN, Knight PR, Murasko DM: Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. ANESTHESIoLogy 1993; 78:700-6
16. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M: Functional role of type I and type II interferons in antiviral defense. Science 1994; 264:1918-21
17. Chakravarthy KV, Bonoiu AC, Davis Wg, Ranjan P, Ding H, Hu R, Bowzard JB, Bergey EJ, Katz JM, Knight PR, Sambhara S, Prasad PN: gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc Natl Acad Sci USA 2010; 107:10172-7
18. Marks LR, Davidson BA, Knight PR, Hakansson AP: Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. MBio 2013; 4:e00438-13
19. Bonville CA, Bennett NJ, Koehnlein M, Haines DM, Ellis JA, DelVecchio AM, Rosenberg HF, Domachowske JB: Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bron-chiolitis. Virology 2006; 349:87-95
20. Raghavendran K, Davidson BA, Mullan BA, Hutson AD, Russo TA, Manderscheid PA, Woytash JA, Holm BA, Notter RH, Knight PR: Acid and particulate-induced aspiration lung injury in mice: Importance of MCP-1. Am J Physiol Lung Cell Mol Physiol 2005; 289:L134-43
21. Davidson BA, Vethanayagam RR, grimm MJ, Mullan BA, Raghavendran K, Blackwell TS, Freeman ML, Ayyasamy V, Singh KK, Sporn MB, Itagaki K, Hauser CJ, Knight PR, Segal BH: NADPH oxidase and Nrf2 regulate gastric aspiration-induced inflammation and acute lung injury. J Immunol 2013; 190:1714-24
22. Lefort J, Motreff L, Vargaftig BB: Airway administration of Escherichia coli endotoxin to mice induces glucocorticoste-roid-resistant bronchoconstriction and vasopermeation. Am J Respir Cell Mol Biol 2001; 24:345-51
23. Tak PP, Firestein gS: NF-kappaB: A key role in inflammatory diseases. J Clin Invest 2001; 107:7-11
24. Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962-70
25. Tovey MG, Lallemand C, Thyphronitis G: Adjuvant activity of type I interferons. Biol Chem 2008; 389:541-5
26. gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35
27. Sica A, Mantovani A: Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 2012; 122:787-95
28. Ayllon J, García-Sastre A: The NS1 protein: A multitasking virulence factor. Curr Top Microbiol Immunol 2015; 386:73-107
29. Meunier I, Von Messling V: NS1-mediated delay of type I interferon induction contributes to influenza A virulence in ferrets. J gen Virol 2011; 92(pt 7):1635-44
30. Bermejo-Martin JF, Ortiz De Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez P, Martin-Loeches I, Varillas D, gallegos MC, Serón C, Micheloud D, gomez JM, Tenorio-Abreu A, Ramos MJ, Molina ML, Huidobro S, Sanchez E, Gordón M, Fernández V, Del Castillo A, Marcos MA, Villanueva B, López CJ, Rodríguez-Domínguez M, galan JC, Cantón R, Lietor A, Rojo S, Eiros JM, Hinojosa C, gonzalez I, Torner N, Banner D, Leon A, Cuesta P, Rowe T, Kelvin DJ: Th1 and Th17 hyper-cytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009; 13:R201
31. Chakravarthy KV, Davidson BA, Helinski JD, Ding H, Law WC, yong KT, Prasad PN, Knight PR: Doxorubicin-conjugated quantum dots to target alveolar macrophages and inflammation. Nanomedicine 2011; 7:88-96